Introduction
"Human chronic myeloid leukemia (CML) is a myeloproliferative disorder (MPD) caused by the Philadelphia chromosome translocation, a t (9; 22) that generates the BCR/ABL fusion oncoprotein" (1) . The BCR-ABL fusion protein is a constitutively active tyrosine kinase. Normally, this kinase precisely regulates downstream genes, including cMyc, Akt and Jun, all of which are major players to the proliferation and survival of normal cells. However, the hyperactivity of the BCR-ABL kinase upsets this fine balance and propels cells towards uncontrolled proliferation and survival, both of which provide a growth advantage to the malignant cells bearing this mutation, ultimately leading to CML (2) . Next generation sequencing has proven to be an effective tool to identify recurrent, specific mutations in solid tumors and leukemias. Although the genetic heterogeneity of cancer necessitates some warn in the interpretation and application of the NGS results (3, 4) , high-throughput sequencing remains a powerful instrument to refine potentially cancer diagnosis and treatment (5) . The aim of this study was to gain insights into the genetic alterations other than BCR-Abl translocation in molecular level, which finally cause CML. We performed whole-exome sequencing of four cases representative of BCR-ABL positive CML in chronic phase of the disease.
Material and Methods
This study was conducted in Tarbiat Modares University Tehran, Iran in 2014. We used exome sequencing technology to identify mutations in molecular level in four individuals with CML who had given informed consent for sample collection and analysis. CML diagnosis was suspected by the Complete Blood Count (CBC) testing and then confirmed by identifying BCR-Abl translocation by real-time PCR. The selected patients were in chronic phase of CML without any other interfering disease and they received no treatment before sampling. DNA was extracted from peripheral blood using the conventional salting-out method. The qualifying DNA samples were exome sequenced by BGI (Beijing Genomics Institute).
Exome sequencing procedures and data analysis
First, genomic DNA was randomly cleaved into a fragment library, purified and subsequently enriched by NimbleGen 2.1M-probe sequence capture array. The enriched library targeting the exome was sequenced on the Illumina HiSeq 2000 platform to acquire paired-end reads with a read length of 90 base pairs. After removing reads containing sequencing adapters and low-quality reads with more than five unknown bases, high-quality reads were aligned with the human genome reference sequence (hg19/GRCh37) using Bowtie2 software 27 with default parameters. The PCR duplicates detected from Alignment files were subsequently removed with Picard (http://picard.sourceforge.net/) to improve alignment accuracy. The Genome Analysis Toolkit (GATK) was then employed for base quality recalibration, local realignment around the potential insertion/deletion (Indel) sites and variant calling. The raw single nucleotide variants were filtered for low mapping quality, low coverage, SNP clusters, etc. Then, the filtered variants were annotated using ANNOVAR for the following parameters: function (exonic or splicing); gene; exonic function (synonymous, nonsynonymous, stop gain, nonframeshift or frameshift indels); amino acid change; conservation; dbSNP (version 135) reference number; allele frequency in 1000 Genomes Project (2012 Feb version).
Results
Data characteristics of exome sequencing of four samples are shown in Table 1 . Statistics of annotated variants in four samples before and after filtering are listed in Table 2 . We also prepared a list of all genes already involved in CML reported in publications summarized in Table 3 . Then we checked all filtered variants in each individual for these known genes to find cancer related genes but we did not identify any pathogenic mutation. Nevertheless, we identified polymorphisms in related genes, some of listed in Table 4 .
Discussion
In this study we performed exome sequencing as a high throughput technology to identify genetic alterations other than BCR-Abl translocation or those that lead to this cytogenetic translocation at molecular level which finally cause CML. We used public databases to prepare a list of cancer genes for further analysis; however, no pathogenic mutation was identified. Moreover, we analyzed functional variants (coding region and splice site variants) bioinformatically, but no pathogenic mutation was found. Logically, there are two main reasons for such results in our survey; disease nature and the technique characteristics.
A chromosomal translocation includes a DNA double strand break and repair more specifically, mis-repair. Missense  rs3734799  Missense  SETBP1  NM_001130110  rs3085861  Frameshift insertion  rs663651  Missense  rs3744825  Missense  FOLR3  NM_000804  rs71891516  Frameshift insertion  PIK3R2  NM_005027  rs1011320  Missense  CD44  NM_001001389  rs9666607  Missense  rs1467558  Missense  AXL  NM_001699  rs7249222  Missense  AKAP13  NM_006738  rs2061821  Missense  rs2061822  Missense  rs2061824  Missense  SLC22A1  NM_003057  rs683369  Missense  rs628031  Missense  PDGFRA  NM_006206  rs35597368  Missense  SON  NM_032195  rs13433428  Missense  rs13047599 Missense Accordingly, all genes implicated in homologous recombination and non-homolegous end joining, as the two main DSB repair pathways, are putative candidate genes mutated before BCR-Abl translocation (6) . Moreover, Alu elements have been involved in the pathogenesis of some complex translocations including BCR and ABL, but these are extremely rare (7) . Leukemogenic chromosomal translocations, including fusions between BCR and ABL are present in the peripheral blood of healthy individuals (8) . It was controversial because for decades it had been proposed that these translocations unavoidably led to leukemia. There are important hints in these results. First, it forcefully implies that this oncogenic translocation is not adequate to produce malignancy, but it instead produces a "pre-malignant" clone that requires additional, complementary, events to transform fully the cell. On the other hand, this result shows that detection of an oncogenic translocation is not equivalent to detection of a malignancy (9, 10) . Second, this result makes a possible explanation for the observation that mice manipulated to overexpress an oncogenic fusion protein often do not grow leukemia. In these mice, one oncogenic mutation is integrated in the mouse germline, but leukemic transformation is not triggered until additional mutation(s) occur spontaneously as the mouse ages. However, most of these putative mutations have not been characterized (6) and we did not identify any pathogenic mutation in related genes as well. In this study; however some polymorphic variants were identified among them; SNPs rs683369 and rs628031 in SLC22A1, found in all subjects, have previously been studied in relation to imatinib response. "SNP rs683369 and advanced disease stage are correlated with a high rate of loss of cytogenetic response or treatment failure to imatinib in CML patients" (11) . We cannot determine the effect of this variant due to the chronic phase of the disease in our patients. Moreover, Chowbay et al. revealed a sub-haplotypic region encompassing one exonic SNP (rs628031) surrounded by two intronic SNPs [IVS6-878C.A (rs3798168) and IVS7+850C.T] that is significantly associated with imatinib clearance (12) . Except rs628031, two other polymorphisms of this sub-haplotypic region were not detected in our subjects. Exome sequencing has been a fast and cost-effective tool to identify recurrent, specific mutations in solid tumors and leukemias (13) (14) (15) . Nevertheless, this recent technique has some limitations too. Two main technical limitations in NGS, which impress exome-sequencing results, are homologous sequences and guanine cytosine (GC) bias (16) which lead to alignment errors. Another technical consideration with exome sequencing is that variants located in UTRs, intronic, promoter, and intergenic regulatory regions are mostly missed. Although it is often difficult to interpret novel variants in such regions, there are known pathogenic variants in many genes that lie outside the exons.
Conclusion
It is the first report of exome sequencing in Philadelphia chromosome positive CML patients. We did not identify any pathogenic mutation in known cancer genes in our patients who can be due to CML pathogenesis or technical limitations.
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